Major Histocompatibility Complex Class I-associated Vaccine Protection from Simian Immunodeficiency Virus-infected Peripheral Blood Cells

Overview

Journal J Exp Med

Specialties Allergy & Immunology
General Medicine

Date 1994 Aug 1

PMID 8046353

Citations 13

Authors

J L Heeney

C van Els

P de Vries

P ten Haaft

N Otting

W Koornstra

J Boes

R Dubbes

H Niphuis

M Dings

M Cranage

S Norley

M Jonker

R E Bontrop

A Osterhaus

Affiliations

Soon will be listed here.

Abstract

To evaluate the effectiveness of vaccine protection from infected cells from another individual of the same species, vaccinated rhesus macaques (Macaca mulatta) were challenged with peripheral blood mononuclear cells from another animal diagnosed with acquired immune deficiency syndrome (AIDS). Half of the simian immunodeficiency virus (SIV)-vaccinated animals challenged were protected, whereas unprotected vaccinates progressed as rapidly to AIDS. Protection was unrelated to either total antibody titers to human cells, used in the production of the vaccine, to HLA antibodies or to virus neutralizing activity. However, analysis of the serotype of each animal revealed that all animals protected against cell-associated virus challenge were those which were SIV vaccinated and which shared a particular major histocompatibility complex (MHC) class I allele (Mamu-A26) with the donor of the infected cells. Cytotoxic T lymphocytes (CTL) specific for SIV envelope protein were detected in three of four protected animals vs. one of four unprotected animals, suggesting a possible role of MHC class I-restricted CTL in protection from infected blood cells. These findings have possible implications for the design of vaccines for intracellular pathogens such as human immunodeficiency virus (HIV).

Citing Articles

Neutralizing Antibody-Based Prevention of Cell-Associated HIV-1 Infection.

Parsons M, Le Grand R, Kent S Viruses. 2018; 10(6).

PMID: 29912167 PMC: 6024846. DOI: 10.3390/v10060333.

Resistance of Major Histocompatibility Complex Class B (MHC-B) to Nef-Mediated Downregulation Relative to that of MHC-A Is Conserved among Primate Lentiviruses and Influences Antiviral T Cell Responses in HIV-1-Infected Individuals.

Mwimanzi F, Toyoda M, Mahiti M, Mann J, Martin J, Bangsberg D J Virol. 2017; 92(1).

PMID: 29046444 PMC: 5730772. DOI: 10.1128/JVI.01409-17.

Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection.

Mooij P, Nieuwenhuis I, Knoop C, Doms R, Bogers W, Ten Haaft P J Virol. 2004; 78(7):3333-42.

PMID: 15016855 PMC: 371051. DOI: 10.1128/jvi.78.7.3333-3342.2004.

Immunization of cats against feline immunodeficiency virus (FIV) infection by using minimalistic immunogenic defined gene expression vector vaccines expressing FIV gp140 alone or with feline interleukin-12 (IL-12), IL-16, or a CpG motif.

Leutenegger C, Boretti F, Mislin C, Flynn J, Schroff M, Habel A J Virol. 2000; 74(22):10447-57.

PMID: 11044089 PMC: 110919. DOI: 10.1128/jvi.74.22.10447-10457.2000.

Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance.

Verschoor E, Mooij P, Oostermeijer H, van der Kolk M, ten Haaft P, Verstrepen B J Virol. 1999; 73(4):3292-300.

PMID: 10074183 PMC: 104093. DOI: 10.1128/JVI.73.4.3292-3300.1999.

References

van Rood J, Balner R, Gabb B, Dersjant H, van Vreeswijk W . Major histocompatibility locus of rhesus monkeys (RhL-A). Nat New Biol. 1971; 230(14):177-80. DOI: 10.1038/newbio230177a0. View

Heeney J, Jonker R, Koornstra W, Dubbes R, Niphuis H, Di Rienzo A . The resistance of HIV-infected chimpanzees to progression to AIDS correlates with absence of HIV-related T-cell dysfunction. J Med Primatol. 1993; 22(2-3):194-200. View

Gelderblom H, Reupke H, Winkel T, Kunze R, Pauli G . MHC-antigens: constituents of the envelopes of human and simian immunodeficiency viruses. Z Naturforsch C J Biosci. 1987; 42(11-12):1328-34. DOI: 10.1515/znc-1987-11-1230. View

Ennis P, Zemmour J, Salter R, Parham P . Rapid cloning of HLA-A,B cDNA by using the polymerase chain reaction: frequency and nature of errors produced in amplification. Proc Natl Acad Sci U S A. 1990; 87(7):2833-7. PMC: 53785. DOI: 10.1073/pnas.87.7.2833. View

BERMAN P, Gregory T, Riddle L, NAKAMURA G, Champe M, Porter J . Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature. 1990; 345(6276):622-5. DOI: 10.1038/345622a0. View

Rotzschke O, Falk K, Deres K, Schild H, Norda M, Metzger J . Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature. 1990; 348(6298):252-4. DOI: 10.1038/348252a0. View

Girard M, Kieny M, Pinter A, Barre-Sinoussi F, Nara P, Kolbe H . Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc Natl Acad Sci U S A. 1991; 88(2):542-6. PMC: 50847. DOI: 10.1073/pnas.88.2.542. View

Miller M, Yamamoto H, Hughes A, Watkins D, Letvin N . Definition of an epitope and MHC class I molecule recognized by gag-specific cytotoxic T lymphocytes in SIVmac-infected rhesus monkeys. J Immunol. 1991; 147(1):320-9. View

Putkonen P, Thorstensson R, Ghavamzadeh L, Albert J, Hild K, Biberfeld G . Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys. Nature. 1991; 352(6334):436-8. DOI: 10.1038/352436a0. View

10.

Prince A, Reesink H, Pascual D, Horowitz B, HEWLETT I, Murthy K . Prevention of HIV infection by passive immunization with HIV immunoglobulin. AIDS Res Hum Retroviruses. 1991; 7(12):971-3. DOI: 10.1089/aid.1991.7.971. View

11.

Watkins D, McAdam S, Liu X, Strang C, Milford E, Levine C . New recombinant HLA-B alleles in a tribe of South American Amerindians indicate rapid evolution of MHC class I loci. Nature. 1992; 357(6376):329-33. DOI: 10.1038/357329a0. View

12.

Fultz P, Nara P, Barre-Sinoussi F, CHAPUT A, Greenberg M, Muchmore E . Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells. Science. 1992; 256(5064):1687-90. DOI: 10.1126/science.256.5064.1687. View

13.

Sabin A . Improbability of effective vaccination against human immunodeficiency virus because of its intracellular transmission and rectal portal of entry. Proc Natl Acad Sci U S A. 1992; 89(18):8852-5. PMC: 50019. DOI: 10.1073/pnas.89.18.8852. View

14.

Chan W, Rodgers A, Hancock R, Taffs F, KITCHIN P, Farrar G . Protection in simian immunodeficiency virus-vaccinated monkeys correlates with anti-HLA class I antibody response. J Exp Med. 1992; 176(4):1203-7. PMC: 2119400. DOI: 10.1084/jem.176.4.1203. View

15.

Heeney J, de Vries P, Dubbes R, Koornstra W, Niphuis H, ten Haaft P . Comparison of protection from homologous cell-free vs cell-associated SIV challenge afforded by inactivated whole SIV vaccines. J Med Primatol. 1992; 21(2-3):126-30. View

16.

Arthur L, Bess Jr J, Sowder 2nd R, Benveniste R, Mann D, Chermann J . Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. Science. 1992; 258(5090):1935-8. DOI: 10.1126/science.1470916. View

17.

Cranage M, Polyanskaya N, McBride B, Cook N, ASHWORTH L, Dennis M . Studies on the specificity of the vaccine effect elicited by inactivated simian immunodeficiency virus. AIDS Res Hum Retroviruses. 1993; 9(1):13-22. DOI: 10.1089/aid.1993.9.13. View

18.

Henderson L, Sowder R, Copeland T, Oroszlan S, Arthur L, Robey W . Direct identification of class II histocompatibility DR proteins in preparations of human T-cell lymphotropic virus type III. J Virol. 1987; 61(2):629-32. PMC: 253995. DOI: 10.1128/JVI.61.2.629-632.1987. View